Oncolytics Biotech (TSE:ONC) has released an update.
Oncolytics Biotech Inc. has successfully conducted its Annual General Meeting, where a significant 41.34% of shareholders participated, resulting in the unanimous re-election of the proposed eight-member board of directors. Additionally, shareholders approved all resolutions, including the appointment of auditors and setting the number of directors for the next year. The company, known for developing the immunotherapeutic agent pelareorep for cancer treatment, continues to move forward with clinical trials aiming for regulatory studies in metastatic breast and pancreatic cancers.
For further insights into TSE:ONC stock, check out TipRanks’ Stock Analysis page.
